Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: A randomised non-inferiority clinical trial

Highlights • Zostavax® is currently administered by SC route, but IM route is common in Europe. • Similar immune responses were observed for both administration routes in gpELISA. • Comparable immune responses were seen for both administration routes in IFN-γ ELISPOT. • IM administration route resul...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2015-02, Vol.33 (6), p.789-795
Main Authors: Diez-Domingo, Javier, Weinke, Thomas, Garcia de Lomas, Juan, Meyer, Claudius U, Bertrand, Isabelle, Eymin, Cécile, Thomas, Stéphane, Sadorge, Christine
Format: Article
Language:English
Subjects:
Age
Aged
Aged, 80 and over
Allergy and Immunology
Antibodies, Viral - blood
Chicken pox
Confidence intervals
Edema - etiology
Edema - physiopathology
Enzyme-Linked Immunospot Assay
Enzymes
Erythema - etiology
Erythema - physiopathology
Female
Herpes zoster
Herpes Zoster - blood
Herpes Zoster - immunology
Herpes Zoster - prevention & control
Herpes Zoster Vaccine - administration & dosage
Herpes Zoster Vaccine - adverse effects
Herpes Zoster Vaccine - immunology
Herpesvirus 3, Human - immunology
Humans
Immune response
Immunogenicity
Infections
Injection
Injections, Intramuscular
Injections, Subcutaneous
Interferon-gamma - blood
Intramuscular administration route
Male
Middle Aged
Pain - etiology
Pain - physiopathology
Prevention
Randomised controlled trial
Shingles
Sub-cutaneous administration route
Vaccination
Vaccines
Vaccines, Attenuated
Varicella zoster virus vaccine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Zostavax® is currently administered by SC route, but IM route is common in Europe. • Similar immune responses were observed for both administration routes in gpELISA. • Comparable immune responses were seen for both administration routes in IFN-γ ELISPOT. • IM administration route resulted in fewer injection-site reactions. • These results support using the IM route for vaccination with Zostavax.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2014.12.024